E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Alzheimer’s Disease is a chronic progressive illness leading to loss of cognitive and intellectual abilities such as memory function, judgement and abstract thinking. In addition to the cognitive deficits the patients experience loss of their ability to take care of instrumental activities of daily living, they are not able to meet the most common requirements of daily life and so they are loosing their independence, needing intensive health care in final stages of the disease. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 7.0 |
E.1.2 | Level | Prim |
E.1.2 | Classification code | 10001896 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate effects of Phenserine-tartrate on cognitive performance using a standardized psychometric test (Cognitive Performance - ADAS-cog) and to evaluate the drug effect on global function involving the caregiver (Global clinical impression of therapeutic effect- CIBIC+) in comparison with Placebo.
|
|
E.2.2 | Secondary objectives of the trial |
Placebo controlled comparison of the efficacy of two different dosages of Phenserine-tartrate, 10mg BID and 15mg BID based on the following endpoints: - Activity of daily living - ADCS - Behavioural/psychiatric symptoms - NPI Effect on Amyloid production -blood plasma and Cerebrospinal fluid (=CSF) concentration of soluble APP, Aß1-40 and Aß1-42 |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
• Signed informed consent by patient or the legally accepted representative prior to the initiation of any study specific procedures • Male or female patients of at least 50 years of age • Probable Alzheimer’s Disease consistent with NINCDS-ADRDA criteria (Appendix 1). • MRI or CT scan within the last 12 months prior to baseline; findings consistent with the diagnosis of probable Alzheimer’s Disease • Mini-Mental state examination score (MMSE) between 24 and 9 inclusive • Modified Hachinsky ischemic score equal or below 4 • Female patients must be at least 2 years post-menopausal or surgically sterile • Caregiver available, if not living in the same household, caregiver sees patient at least 4 times a week • Patients living at home, old people’s home or an institutional setting without continuous nursing care • General health status acceptable for a participation in a 6 month clinical trial |
|
E.4 | Principal exclusion criteria |
• Violation of inclusion criteria not approved by clinical study director or study safety officer • Failure to perform or to evaluate screening or baseline examinations • Hospitalisation (except for study purposes or due to social reasons, e.g. hospitalisation to unburden the caregiver) or change of concomitant medication 4 weeks prior to screening or during screening period • Participation in another therapeutic clinical trial 3 months before baseline • Inability to swallow tablets
Medical • Unsubstituted vitamin B12 or folate deficiency • Serum electrolytes (sodium, potassium, magnesium) out of normal range • Unsubstituted hypothyroidism with TSH > 6,00 µU/ml • Juvenile onset diabetes mellitus • Adult onset diabetes mellitus insufficiently controlled (HbA1c > 8 %) • Renal insufficiency with serum creatinine > 2mg/dl • Severe hypotension requiring treatment with more than 2 drugs • Lab values seriously abnormal, and/or more than 2 lab values abnormal not approved by clinical study director or study safety officer • Hypersensitivity to cholinergic drugs • Serious drug allergies • Malignant tumours within the last 5 years Cardiovascular • Myocardial infarction or unstable angina within the last 6 months before screening • History of more than 1 myocardial infarction during the last 5 years • Cardiomyopathy • Myocarditis • Atrial fibrillation • Severe hypotension requiring treatment with more than 2 drugs • Severe hypertension requiring treatment with more than 2 drugs • Bradycardia (frequency of heart beat < 50/min.) • Tachycardia (frequency of heart beat > 90/min.) • Presence of AV block (type II / Mobitz II and type III) • Congenital long QT syndrome • Sinus node dysfunction • Prolonged QTcB-interval (males > 450 and females > 470 msec) • QTcB dispersion > 100 msec • Presence of U wave Psychiatric • Episode of major depression in medical history • GDS score (15 item scale) > 5 • History or presence of schizophrenia • Chronic intoxication or chronic substance use disorder with pharmaceuticals, drugs, alcohol or industrial poisons
Neurological • Stroke within 6 months before screening or concomitant with onset of dementia • Tumours, subdural haematoma or other space occupying processes on CT/MRI • Head trauma with loss of consciousness within 1 year before or concurrent with onset of dementia • Onset of dementia within 1 year following cardiac arrest, surgery with general anaesthesia or resuscitation • Degenerative CNS disease, e.g. M. Huntington, Jacob-Creutzfeld disease, Downs syndrome • Wernickes encephalopathy • Acute or chronic CNS infection including tertiary syphilis Previous Medication • Acetylcholinesterase inhibitors 3 months before baseline • Any experimental drug 3 months before enrolment • Nootropics 1 month before screening • Promethazine, thioridazine, chlorprothixene, flunitrazepam or nitrazepam not discontinued 2 weeks before screening • Antipsychotics if not given for sleep disturbances • Antidepressants, except stable treatment with SSRI´s for at least 3 months prior to screening Concomitant Medication • Peripherally acting drugs with effects on cholinergic transmission • Immunosuppresants • Antiparkinsonian therapy • Antiepileptics • Centrally active anti-hypertensive drugs like clonidine, alpha methyl dopa, guanidine, guanfacine or moxonidine • Non-steroidal anti-inflammatory drugs 72 h before blood plasma or CSF sampling • Cholesterol lowering drugs inhibiting HMG CoA reductase (simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin) • Chronic intake of opioid containing analgesics • Sedating H1 antihistamines • Systemic cortico-steroids CSF sampling • Thrombocytopenia with platelet count < 140*103/µl • Coagulation disorders • Local skin or soft tissue infection along the needle tract • Papilledema during funduscopy • Evidence of high CSF pressure in CT/MRI |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Placebo controlled comparison of the efficacy of two different dosages of Phenserine-tartrate, 10mg BID and 15mg BID based on the following endpoints: • Cognitive Performance - ADAS-cog+ • Global clinical impression of therapeutic effect- CIBIC+ |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Information not present in EudraCT |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
150 patients will be recruited. Non-evaluable patients will be replaced until the specified total is archieved. Patients will receive Phenserine-tartrate 15mg BID, 10mg BID or placebo, according to a 2:2:1 randomisation in favour of the active treatment doses. The duration of the treatment for each patient will be 6 month. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |